Med Ed 101

JULY 30, 2023

After my recent post on my top 5 medication/vitamin interactions, I received the request to cover medications that deplete vitamins and minerals. I loved this idea because it is an important consideration in clinical practice! Keep in mind that these often show up on pharmacology and board exams as well! Without further ado, here are […] The post Medications That Deplete Vitamins And Minerals – Top 10 appeared first on Med Ed 101.

98

98

The Checkup by Singlecare

JULY 30, 2023

Xanax is a brand-name anti-anxiety medication commonly prescribed to adults with anxiety , or generalized anxiety disorder. Xanax can also be used to treat panic disorder. Xanax contains the active ingredient alprazolam. Xanax is classified as a benzodiazepine drug. It works by binding to gamma-aminobutyric acid (GABA) receptors in the brain, producing a calming and sedating effect.

Dosage 52

Dosage Labelling FDA Controlled Substances 52

pharmaphorum

JULY 30, 2023

FDA rejects Citius' revived IL-2 therapy for lymphoma Phil.

FDA 74

FDA 74

PharmExec

JULY 30, 2023

Webinar Date/Time: Tue, Sep 12, 2023 10:00 AM EDT | 9:00 AM CT | 3:00 PM BST | 4:00 PM CEST

HIPAA 52

HIPAA 52

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharmaceutical Technology

JULY 30, 2023

Pelabresib is a small molecule commercialized by MorphoSys, with a leading Phase III program in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF).

40

40

Pharmaceutical Technology

JULY 30, 2023

Pelabresib is a small molecule commercialized by MorphoSys, with a leading Phase III program in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF).

40

40

Pharmaceutical Technology

JULY 30, 2023

Gedeptin is a gene therapy commercialized by GeoVax Labs, with a leading Phase II program in Recurrent Head And Neck Cancer Squamous Cell Carcinoma.

40

40

Pharmaceutical Technology

JULY 30, 2023

Vamorolone is a small molecule commercialized by Catalyst Pharmaceuticals, with a leading Pre-Registration program in Duchenne Muscular Dystrophy.

40

40

Pharmaceutical Technology

JULY 30, 2023

Nirogacestat hydrobromide is a small molecule commercialized by SpringWorks Therapeutics, with a leading Pre-Registration program in Benign Tumor.

40

40

Pharmaceutical Technology

JULY 30, 2023

Vamorolone is a small molecule commercialized by Catalyst Pharmaceuticals, with a leading Pre-Registration program in Duchenne Muscular Dystrophy.

40

40

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Pharmaceutical Technology

JULY 30, 2023

Nirogacestat hydrobromide is a small molecule commercialized by SpringWorks Therapeutics, with a leading Pre-Registration program in Benign Tumor.

40

40

Pharmaceutical Technology

JULY 30, 2023

FPI-1434 is a monoclonal antibody conjugated commercialized by Fusion Pharmaceuticals, with a leading Phase II program in Endometrial Cancer.

40

40

Pharmaceutical Technology

JULY 30, 2023

PF-06480605 is a monoclonal antibody commercialized by Pfizer, with a leading Phase II program in Crohn's Disease (Regional Enteritis).

40

40

Pharmaceutical Technology

JULY 30, 2023

PF-06480605 is a monoclonal antibody commercialized by Pfizer, with a leading Phase II program in Crohn's Disease (Regional Enteritis).

40

40

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Pharmaceutical Technology

JULY 30, 2023

CAP-1002 is a cell therapy commercialized by Nippon Shinyaku, with a leading Phase III program in Duchenne Muscular Dystrophy.

40

40

Pharmaceutical Technology

JULY 30, 2023

CAP-1002 is a cell therapy commercialized by Nippon Shinyaku, with a leading Phase III program in Duchenne Muscular Dystrophy.

40

40

Pharmaceutical Technology

JULY 30, 2023

BNT-321 is a monoclonal antibody commercialized by BioNTech, with a leading Phase II program in Metastatic Colorectal Cancer.

40

40

Pharmaceutical Technology

JULY 30, 2023

BNT-321 is a monoclonal antibody commercialized by BioNTech, with a leading Phase II program in Metastatic Colorectal Cancer.

40

40

Pharmaceutical Technology

JULY 30, 2023

Resiniferatoxin is a small molecule commercialized by Shionogi, with a leading Phase III program in Osteoarthritis Pain.

40

40

Pharmaceutical Technology

JULY 30, 2023

BGB-3245 is a small molecule commercialized by SpringWorks Therapeutics, with a leading Phase II program in Solid Tumor.

40

40

Pharmaceutical Technology

JULY 30, 2023

Resiniferatoxin is a small molecule commercialized by Shionogi, with a leading Phase III program in Osteoarthritis Pain.

40

40